LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy therapies, announced a $105 million (€90 million) global license and transfer ...

LEO is claiming global commercial rights to Spevigo for GPP, but will also collaborate with Boehringer on potential follow-up ...

BI 1815368, a potential oral treatment to improve vision in patients with diabetic macular edema, is being investigated in a ...

LEO Pharma acquires global rights to Spevigo for $105M, boosting its dermatology pipeline and expanding access for patients ...

Virtual wards, extra health care appointments and a huge boost in vaccinations are among the keys to improving healthcare across Hampshire over the next ten years, health bosses have said.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Patients with atopic dermatitis experienced improvements in severity with 16 weeks of tralokinumab despite the number of ...

Get the latest research in feeding and managing pregnant beef cows and heifers at the Pearls of Production: Women in ...

Patients with connective tissue disease-related interstitial lung disease show slower decline in lung function and longer ...

Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atrial Fibrillation ...